Judge refuses to toss case alleging MedStar conspired with revenue cycle vendor in false billing scheme

A federal judge refused to dismiss a whistle-blower complaint against Columbia, Md.-based MedStar Health on March 22, according to Bloomberg BNA.

Advertisement

The complaint, filed by a former MedStar employee, alleges the system conspired with revenue cycle vendor Accretive Health, which is now R1 RCM, to increase the number of inpatient admissions at its hospitals by changing recommended treatments for Medicare patients, according to the report.

The whistle-blower alleges the purpose of the scheme was to provide a revenue boost for MedStar.

“Accretive induced hospital administrators to override both the professional integrity of their hospitals’ own doctors and the fiscal integrity of the Medicare system,” Brad Pigott of Pigott & Johnson in Jackson, Miss., who is representing the whistle-blower, told Bloomberg BNA.

MedStar declined to comment on the lawsuit, saying the system does not comment on ongoing litigation. R1 RCM did not immediately respond to Becker’s request for comment.

More articles on legal and regulatory issues:

Man accused of attacking nurse at Wisconsin hospital
8 latest healthcare industry lawsuits
Illinois Supreme Court leaves hospital property tax exemptions in place

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Download Whitepaper

The cost-saving opportunity most health systems overlook

Many hospitals and health systems scrutinize staffing, service lines, and payer contracts for savings. Fewer look at one of their largest assets: real estate.…

Advertisement

Next Up in Legal & Regulatory Issues

Advertisement

Comments are closed.